STOCK TITAN

Dr. Reddy’s (NYSE: RDY) allots 12,100 ESOP shares, updates capital

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
6-K

Rhea-AI Filing Summary

Dr. Reddy’s Laboratories Limited reported the allotment of 12,100 equity shares of Re.1 each on June 5, 2026 to eligible employees who exercised stock options. The shares were issued under the Dr. Reddy’s Employees Stock Option Scheme, 2002 and the Employees ADR Stock Option Scheme, 2007.

After this issue, total issued shares stand at 83,46,70,070 and total issued share capital is Rs. 83,46,70,070. The new shares carry no premium, rank pari passu with existing equity shares, and are of the same ISIN INE089A01031.

Positive

  • None.

Negative

  • None.
ESOP shares issued 12,100 equity shares Allotted on June 5, 2026 under employee stock option schemes
Par value per share Re.1 per share Par value of newly allotted equity shares
Total issued shares after issue 83,46,70,070 shares Total issued equity shares after ESOP allotment
Total issued share capital Rs. 83,46,70,070 Issued share capital after ESOP allotment
Forfeited shares 1,000 shares Forfeited in September 1988 for non-payment of allotment money
ISIN of shares INE089A01031 ISIN for the company’s equity shares including new allotment
Employees Stock Option Scheme financial
"exercise of their Stock Options under Dr. Reddy’s Employees Stock Options Scheme, 2002"
ADR Stock Option Scheme financial
"Dr. Reddy’s Employees ADR Stock Option Scheme, 2007"
pari passu financial
"Yes, the shares rank pari passu with the existing shares"
An instruction that different claims, securities, or creditors are treated equally and share rights or payments on the same priority level. For investors, it means their position will be paid or have voting power alongside others in the same class rather than being favored or subordinated—think of several people standing in one bus line who all get on together rather than some cutting ahead. That parity affects expected recovery in reorganizations, dividend order, and relative risk.
SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021 regulatory
"details as required under Regulation 10(c) of the SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021"
ISIN financial
"ISIN Number of the shares if issued in Demat: INE089A01031"
A 12-character International Securities Identification Number (ISIN) is a unique code that acts like a passport for a specific stock, bond or other tradable security so it can be identified worldwide. Investors and systems use it to ensure they are buying, selling and tracking the exact same instrument across exchanges and data feeds, which prevents costly mix-ups and makes portfolio reporting, settlement and regulatory checks simpler and more reliable.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
 


SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

June, 2026

 

Commission File Number 1-15182

 

DR. REDDY’S LABORATORIES LIMITED

(Translation of registrant’s name into English)

 

8-2-337, Road No. 3, Banjara Hills

Hyderabad, Telangana 500 034, India

+91-40-49002900

 

(Address of principal executive office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F  x                                Form 40-F  ¨

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  ______

 

Note:  Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  ______

 

Note:  Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant’s “home country”), or under the rules of the home country exchange on which the registrant’s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant’s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.

 

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

 

Yes  ¨                                      No  x

 

If “Yes” is marked, indicate below the file number assigned to registrant in connection with Rule 12g3-2(b): 82-________.


 

 

EXHIBITS

 

Exhibit
Number

  

Description of Exhibits

 

 

 

99.1


Intimation dated June 5, 2026

 

2

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 

DR. REDDY’S LABORATORIES LIMITED

(Registrant)

 

 

Date: June 5, 2026   

By:

/s/ K Randhir Singh

 

 

Name:

K Randhir Singh

 

 

Title:

Company Secretary

 

3

 

Exhibit 99.1


Dr. Reddy's Laboratories Ltd.

8-2-337, Road No. 3, Banjara Hills

Hyderabad – 500 034, Telangana, India

 

CIN: L85195TG1984PLC004507

 

Tel:       + 91 40 4900 2900

Fax:     + 91 40 4900 2999

Email:  mail@drreddys.com

Web:    www.drreddys.com


June 5, 2026

 

National Stock Exchange of India Ltd. (Scrip Code: DRREDDY)

BSE Ltd. (Scrip Code: 500124)

New York Stock Exchange Inc. (Stock Code: RDY)

NSE IFSC Ltd. (Stock Code: DRREDDY)

 

Dear Sir/Madam,

 

Ref:

Disclosure under Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015

 

Sub: Allotment of Equity Shares on exercise of Stock Options under ESOPs

 

This is to inform you that the Company has allotted 12,100 equity shares of Re.1/- each of the Company, fully paid up, on June 5, 2026, to eligible employees pursuant to exercise of their Stock Options under Dr. Reddy’s Employees Stock Options Scheme, 2002 and Dr. Reddy’s Employees ADR Stock Options Scheme, 2007.

 

Further, please find enclosed the details as required under Regulation 10(c) of the SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021.

 

Thanking you.

 

Yours faithfully,

For Dr. Reddy’s Laboratories Limited

K Randhir Singh

Company Secretary, Compliance Officer & Head-CSR

 

Encl: as above

 

 

Dr. Reddy's Laboratories Ltd.

8-2-337, Road No. 3, Banjara Hills

Hyderabad – 500 034, Telangana, India

 

CIN: L85195TG1984PLC004507

 

Tel:       + 91 40 4900 2900

Fax:     + 91 40 4900 2999

Email:  mail@drreddys.com

Web:    www.drreddys.com

 

Details under Regulation 10(c) of the SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021

 

1

Company name and address of Registered Office:
Dr. Reddy's Laboratories Limited
8-2-337, Road No.3, Banjara Hills, Hyderabad – 500034

2

Name of the Stock Exchanges on which the company’s shares are listed:
BSE Limited
National Stock Exchange of India Limited
New York Stock Exchange Inc. (ADRs)

NSE IFSC Limited (ADRs)

3

Filing date of the statement referred in Regulation 10(b) of the SEBI (Share Based Employee Benefits) Regulations, 2021 with Stock Exchange:

 

The Schemes were institutionalised under the erstwhile the SEBI (Employee Stock Option Scheme and Employee Stock Purchase Scheme) Guidelines, 1999 and appropriate details under Schedule V were filed. The Schemes comply with provisions of the SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021.

4

Filing Number, if any: NA

5

Title of the Scheme pursuant to which shares are issued, if any:

Dr. Reddys Employees Stock Option Scheme, 2002

Dr. Reddy’s Employees ADR Stock Option Scheme, 2007.

6

Kind of security to be listed: Equity Shares

7

Par value of the shares: Re. 1/-

8

Date of issue of shares: June 5, 2026 (Date of allotment on exercise)

9

Number of shares issued: 12,100 equity shares

10

Share Certificate No., if applicable: NA

11

Distinctive number of the share, if applicable: 834656971 to 834669070

12

ISIN Number of the shares if issued in Demat: INE089A01031

13

Exercise price per share: 12,100 shares at Re.1/- each

14

Premium per share: NIL

 15

Total Issued shares after this issue: 83,46,70,070 (*)

16

Total Issued share capital after this issue: Rs. 83,46,70,070 /-

17

Details of any lock-in on the shares: NA

18

Date of expiry of lock-in:  NA

19

Whether shares identical in all respects to existing shares if not, when will they become identical?
Yes, the shares rank pari passu with the existing shares

20

Details of listing fees, if payable: NA

 

(*) Total paid up capital after this issue: 83,46,69,070 equity shares of Re.1 each, aggregating to Rs. 83,46,69,070/- (difference of 1,000 due to forfeited shares of Re. 1/- each in September 1988 on account of non-payment of allotment money.)

​​​​​​​

 

FAQ

What did Dr. Reddy’s Laboratories (RDY) announce in this Form 6-K?

Dr. Reddy’s announced it allotted 12,100 equity shares of Re.1 each on June 5, 2026 to employees exercising stock options under its 2002 and 2007 ESOP schemes, modestly increasing its issued share capital.

How many new shares did Dr. Reddy’s (RDY) issue under its ESOPs?

The company issued 12,100 new equity shares of Re.1 each. These shares were allotted to eligible employees who exercised stock options granted under Dr. Reddy’s 2002 and ADR 2007 employee stock option schemes.

What is Dr. Reddy’s (RDY) total issued share capital after this ESOP allotment?

After the ESOP allotment, total issued share capital is Rs. 83,46,70,070, representing 83,46,70,070 equity shares of Re.1 each. A note explains a difference of 1,000 due to forfeited shares from 1988.

Are the new Dr. Reddy’s (RDY) ESOP shares identical to existing equity shares?

Yes, the newly issued 12,100 equity shares rank pari passu with existing shares. This means they carry the same rights and characteristics as current equity, including dividends and voting rights, and share the same ISIN INE089A01031.

Under which schemes were the new Dr. Reddy’s (RDY) ESOP shares issued?

The shares were issued under Dr. Reddy’s Employees Stock Option Scheme, 2002 and the Employees ADR Stock Option Scheme, 2007. Both schemes comply with SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021.

Filing Exhibits & Attachments

1 document